Home

FDA Approves New Glaucoma Medications

Wed, 03/28/2001 - 1:00am — Karen Stevenson
Description: 

The Food and Drug Administration (FDA) announced the approval of two new drugs, Lumigan and Travatan, to treat the elevated intraocular pressure which is often associated with glaucoma. These drugs are intended as additional alternatives for the reduction of intraocular pressure in patients who are intolerant of other intraoular lowering medications, or in patients who have had insufficient responses to other intraocular pressure lowering medications. Many of these patients might otherwise need surgery for management of their glaucoma.

Glaucoma, a leading cause of irreversible blindness in the world, is the second most common cause of blindness in the United States and affects about two million older Americans. Lumigan will be marketed by Allergan, Inc. of Irvine, California. Travatan will be marketed by Alcon Universal, Ltd of Fort Worth, Texas.

The Food and Drug Administration (FDA) announced the approval of two new drugs, Lumigan and Travatan, to treat the elevated intraocular pressure which is often associated with glaucoma. These drugs are intended as additional alternatives for the reduction of intraocular pressure in patients who are intolerant of other intraoular lowering medications, or in patients who have had insufficient responses to other intraocular pressure lowering medications. Many of these patients might otherwise need surgery for management of their glaucoma.

Glaucoma, a leading cause of irreversible blindness in the world, is the second most common cause of blindness in the United States and affects about two million older Americans. Lumigan will be marketed by Allergan, Inc. of Irvine, California. Travatan will be marketed by Alcon Universal, Ltd of Fort Worth, Texas.